<DOC>
	<DOCNO>NCT02336633</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic potential Resveratrol caudate volume HD patient , use volumetric MRI .</brief_summary>
	<brief_title>Resveratrol Huntington Disease</brief_title>
	<detailed_description>Thanks neuroimaging biomarkers already validate HD newly identify metabolic brain biomarkers use 31P-MRS , test reduction neurodegeneration among HD patient result improvement brain energy profile resveratrol . We plan randomize 102 early affected HD patient ( maximum 120 included patient ) France ( 5≤UHDRS≤40 ) randomize , double-blind , control study . Patients receive either resveratrol 80 mg ( n=51 ) , placebo ( n=51 ) 12 month . Clinical benefit respectively evaluate UHDRS neuropsychiatric questionnaire ; biological tolerance evaluate routine biochemical blood test plasma measurement resveratrol , three factor test every three month . The primary end-point measure rate caudate atrophy - sensitive biomarker identify date HD - one year treatment resveratrol early affect HD patient use volumetric MRI described . Secondary end-points include : The clinical biological tolerance resveratrol HD patient evaluate ( ) neuropsychiatric questionnaire : Starkstein apathy scale , Hospital Anxiety Depression Scale ( HADS ) , Systems Behaviour Inventory ( FrSBe ) SF36 , ( ii ) cognitive test ; Symbol Digit Modalities Test ( SDMT ) ( iii ) routine biochemical test The clinical benefit resveratrol evaluate decrease progression UHDRS year treatment The benefit resveratrol brain energy metabolism evaluate restoration increase ratio inorganic phosphate/phosphocreatine - reflect normal brain activation - visual stimulation , use 31P-MRS describe The progression caudate atrophy year correlate change brain energy profile well change progression UHDRS . The compliance treatment peak plasmatic concentration plasma measurement resveratrol .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Inclusion criterion : Positive genetic test CAG repeat length &gt; 39 HTT gene At least 18 year age Signature inform consent Covered social security UHDRS score 5 40 ( include ) Ability undergo MRI scan Exclusion criterion : Hypersensitivity resveratrol one excipients ( gelatin glycerin ) Tetrabenazine treatment Neuroleptic treatment olanzapine small dos ( ≤10 mg ) Abilify® ( ≤15mg ) VKA treatment ( Previscan® , Sintron® , Coumadine® ) NACO treatment ( Pradaxa® , Xarelto® , Eliquis® ) Additional psychiatric neurological condition Severe head injury Participation another therapeutic trial ( 3 month exclusion period ) Pregnancy breastfeed Inability understand information protocol Persons deprive liberty judicial administrative decision Adult subject legal protection unable consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Huntington disease</keyword>
	<keyword>Neurodegenerative disease</keyword>
	<keyword>Volumetric MRI</keyword>
	<keyword>31P MR spectroscopy</keyword>
	<keyword>metabolism</keyword>
	<keyword>Caudate atrophy</keyword>
</DOC>